Candel Therapeutics, Inc.
117 Kendrick Street
Suite 450
Needham, MA 02494
United States
617 916 5445
https://www.candeltx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 42
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D. | President, CEO & Director | 1.12M | 無 | 1961 |
| Dr. Estuardo Aguilar-Cordova Inf., M.D., Ph.D. | Founder & Director | 35k | 無 | 1959 |
| Dr. Francesca Barone M.D., Ph.D. | Chief Scientific Officer | 506.76k | 無 | 1978 |
| Mr. Charles Schoch | Interim CFO, VP of Finance & Corporate Controller | 無 | 無 | 1985 |
| Dr. Seshu Tyagarajan Ph.D. | Chief Technical & Development Officer | 335.27k | 無 | 1968 |
| Ms. Ileen B. Winick | Chief People Officer | 無 | 無 | 無 |
| Ms. Susan Stewart J.D., L.L.M. | Chief Regulatory Officer | 無 | 無 | 1961 |
| Dr. William Garrett Nichols M.D., M.S. | Chief Medical Officer | 無 | 無 | 1969 |
描述
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
公司管治
截至 無 止，Candel Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
